FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082043397> ?p ?o ?g. }

• W3082043397 endingPage "4058" @default.
• W3082043397 startingPage "4058" @default.
• W3082043397 abstract "Abstract The unprecedented success of checkpoint blockade therapies clearly demonstrates the power of the immune system to fight cancer. Yet, only a minority of cancer patients respond with long-term control of the tumor or even cure, necessitating the development of other treatment modalities. Hookipa Pharma developed a novel attenuated, replication-competent viral vector platform (TheraT) that induces powerful cytotoxic T lymphocyte responses against foreign and self-antigens. In a preclinical model for human papilloma virus 16 (HPV16) associated cancer (TC-1), we evaluated immunogenicity and efficacy upon systemic and intratumoral application of TheraT vectors based on the arenaviruses lymphocytic choriomeningitis virus (LCMV) and pichinde virus (PICV). Both HB-201 (LCMV) and HB-202 (PICV) product candidates encode a non-oncogenic but highly antigenic E6/E7 fusion protein from HPV16. Independent of the route of administration, single administration of HB-201 or HB-202 induced potent peripheral E7-specific CD8+ T cell responses and led to efficient tumor growth control. Survival of TheraT treated animals was significantly longer compared to buffer treated animals. Similarly, single systemic as well as intratumoral application of HB-201 or HB-202 induced major infiltration of CD8+ T cells into the tumor microenvironment. Combination of intravenous HB-201 and anti-PD1 was well tolerated but did not further enhance efficacy in this model, implicating the presence of other immune evasion factors. In conclusion, replication-attenuated TheraT is safe, highly immunogenic and shows excellent therapeutic efficacy after single intravenous and intratumoral application. These data underline the potential and versatility of this novel vector platform. Mechanistic studies in various mouse tumor models are underway. Phase 1/2 clinical trial initiation of HB-201 monotherapy is planned for end of 2019 and preparations for an IND filing for a combination trial of HB-201 and HB-202 in H1 2020 have been initiated. Citation Format: Josipa Raguz, Sarah Schmidt, Theresa Kleisner, Manuel Zerbs, Goran Bekic, Sonja Feher, Daniel Oeler, Felix Stemeseder, Ursula Berka, Bettina Kiefmann, Sophie Schulha, Igor Matushansky, Henning Lauterbach, Klaus Orlinger. TheraT - a highly versatile arenavirus based vector platform for intravenous and intratumoral cancer immunotherapy [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4058." @default.
• W3082043397 created "2020-09-08" @default.
• W3082043397 creator A5001648154 @default.
• W3082043397 creator A5010893584 @default.
• W3082043397 creator A5017334913 @default.
• W3082043397 creator A5017789346 @default.
• W3082043397 creator A5017955674 @default.
• W3082043397 creator A5024550697 @default.
• W3082043397 creator A5026381010 @default.
• W3082043397 creator A5029460675 @default.
• W3082043397 creator A5030100141 @default.
• W3082043397 creator A5042256729 @default.
• W3082043397 creator A5052143442 @default.
• W3082043397 creator A5065804797 @default.
• W3082043397 creator A5069532813 @default.
• W3082043397 creator A5066643821 @default.
• W3082043397 date "2020-08-15" @default.
• W3082043397 modified "2023-10-18" @default.
• W3082043397 title "Abstract 4058: TheraT - a highly versatile arenavirus based vector platform for intravenous and intratumoral cancer immunotherapy" @default.
• W3082043397 doi "https://doi.org/10.1158/1538-7445.am2020-4058" @default.
• W3082043397 hasPublicationYear "2020" @default.
• W3082043397 type Work @default.
• W3082043397 sameAs 3082043397 @default.
• W3082043397 citedByCount "2" @default.
• W3082043397 countsByYear W30820433972023 @default.
• W3082043397 crossrefType "journal-article" @default.
• W3082043397 hasAuthorship W3082043397A5001648154 @default.
• W3082043397 hasAuthorship W3082043397A5010893584 @default.
• W3082043397 hasAuthorship W3082043397A5017334913 @default.
• W3082043397 hasAuthorship W3082043397A5017789346 @default.
• W3082043397 hasAuthorship W3082043397A5017955674 @default.
• W3082043397 hasAuthorship W3082043397A5024550697 @default.
• W3082043397 hasAuthorship W3082043397A5026381010 @default.
• W3082043397 hasAuthorship W3082043397A5029460675 @default.
• W3082043397 hasAuthorship W3082043397A5030100141 @default.
• W3082043397 hasAuthorship W3082043397A5042256729 @default.
• W3082043397 hasAuthorship W3082043397A5052143442 @default.
• W3082043397 hasAuthorship W3082043397A5065804797 @default.
• W3082043397 hasAuthorship W3082043397A5066643821 @default.
• W3082043397 hasAuthorship W3082043397A5069532813 @default.
• W3082043397 hasConcept C121608353 @default.
• W3082043397 hasConcept C126322002 @default.
• W3082043397 hasConcept C147483822 @default.
• W3082043397 hasConcept C154317977 @default.
• W3082043397 hasConcept C159047783 @default.
• W3082043397 hasConcept C167672396 @default.
• W3082043397 hasConcept C202751555 @default.
• W3082043397 hasConcept C203014093 @default.
• W3082043397 hasConcept C2522874641 @default.
• W3082043397 hasConcept C2777701055 @default.
• W3082043397 hasConcept C2779574689 @default.
• W3082043397 hasConcept C2780190958 @default.
• W3082043397 hasConcept C2780674031 @default.
• W3082043397 hasConcept C2780851360 @default.
• W3082043397 hasConcept C2780868878 @default.
• W3082043397 hasConcept C502942594 @default.
• W3082043397 hasConcept C55493867 @default.
• W3082043397 hasConcept C71924100 @default.
• W3082043397 hasConcept C86803240 @default.
• W3082043397 hasConcept C8891405 @default.
• W3082043397 hasConceptScore W3082043397C121608353 @default.
• W3082043397 hasConceptScore W3082043397C126322002 @default.
• W3082043397 hasConceptScore W3082043397C147483822 @default.
• W3082043397 hasConceptScore W3082043397C154317977 @default.
• W3082043397 hasConceptScore W3082043397C159047783 @default.
• W3082043397 hasConceptScore W3082043397C167672396 @default.
• W3082043397 hasConceptScore W3082043397C202751555 @default.
• W3082043397 hasConceptScore W3082043397C203014093 @default.
• W3082043397 hasConceptScore W3082043397C2522874641 @default.
• W3082043397 hasConceptScore W3082043397C2777701055 @default.
• W3082043397 hasConceptScore W3082043397C2779574689 @default.
• W3082043397 hasConceptScore W3082043397C2780190958 @default.
• W3082043397 hasConceptScore W3082043397C2780674031 @default.
• W3082043397 hasConceptScore W3082043397C2780851360 @default.
• W3082043397 hasConceptScore W3082043397C2780868878 @default.
• W3082043397 hasConceptScore W3082043397C502942594 @default.
• W3082043397 hasConceptScore W3082043397C55493867 @default.
• W3082043397 hasConceptScore W3082043397C71924100 @default.
• W3082043397 hasConceptScore W3082043397C86803240 @default.
• W3082043397 hasConceptScore W3082043397C8891405 @default.
• W3082043397 hasIssue "16_Supplement" @default.
• W3082043397 hasLocation W30820433971 @default.
• W3082043397 hasOpenAccess W3082043397 @default.
• W3082043397 hasPrimaryLocation W30820433971 @default.
• W3082043397 hasRelatedWork W1409541451 @default.
• W3082043397 hasRelatedWork W1598089960 @default.
• W3082043397 hasRelatedWork W2032986687 @default.
• W3082043397 hasRelatedWork W2033002585 @default.
• W3082043397 hasRelatedWork W2040099078 @default.
• W3082043397 hasRelatedWork W2096931909 @default.
• W3082043397 hasRelatedWork W2156242955 @default.
• W3082043397 hasRelatedWork W2171386548 @default.
• W3082043397 hasRelatedWork W2327043232 @default.
• W3082043397 hasRelatedWork W4360983034 @default.
• W3082043397 hasVolume "80" @default.
• W3082043397 isParatext "false" @default.
• W3082043397 isRetracted "false" @default.
• W3082043397 magId "3082043397" @default.

• next